好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Initial Validity and Clinical Utility of the Moticon Insole System for Assessing Gait in Parkinson’s Disease
Movement Disorders
P11 - Poster Session 11 (8:00 AM-9:00 AM)
5-015

To establish the clinical validity of digital insoles against a gold standard gait analysis system for measuring select spatiotemporal gait parameters in patients with PD and explore how these relate to overall disease severity and responsiveness to dopaminergic therapy.

The measurement of gait abnormalities in Parkinson’s disease (PD) have traditionally used gait labs and equipment, which are expensive and require specific training in analysis. Digital gait technologies that may be more user-friendly, and cost-effective than traditional gait analysis systems.

A comparative analysis between digital insoles (Moticon ReGoTM) and the GAITRite system was conducted on patients with PD during a single on-site visit. Patients were assessed the OFF and ON levodopa states by neurologists. Gait cadence, speed, stride length, and stance, swing and double support time were measured simultaneously with both systems during two 10-meter walk tests (self-selected pace); agreement was evaluated using ICCs. Linear mixed models were used to estimate mean differences in gait parameters between the ON/OFF states and test for associations with MDS-UPDRS motor scores. 
Twenty-one patients with PD and a mean age of 64.2±10.5 years, disease duration of 9.6±5.7 years, and MDS-UPDRS motor score of 43.4±18.3 (OFF) were enrolled across two sites. Analytical validation for gait cadence, speed, and stride length showed excellent agreement (ICCs: 0.93–0.97). Stance, swing, and double support times exhibited lower validity with moderate agreement (ICCs: 0.48–0.57). Gait speed and stride length were significantly associated with MDS-UPDRS motor scores. Mean differences in all parameters measured with the insoles except cadence were significantly different between OFF/ON states (p<0.009).

These findings support the validity of digital insoles for gait cadence, speed, and stride length in PD.  The association of select gait parameters with disease severity and dopaminergic ON or OFF states suggests their potential use as a quantitative outcome measure in PD.
Authors/Disclosures
Deborah H. Hall, MD, PhD, FAAN (Rush University)
PRESENTER 		Dr. Hall has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier - Parkinsonism and Related Disorders. Dr. Hall has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology. The institution of Dr. Hall has received research support from Parkinson's Foundation. The institution of Dr. Hall has received research support from CHDI. The institution of Dr. Hall has received research support from Uniqure. The institution of Dr. Hall has received research support from NIH.
Kimberly Kwei, MD, PhD (Neurological Institute) The institution of Dr. Kwei has received research support from New York Community Trust.
Nicollette L. Purcell, PhD Dr. Purcell has nothing to disclose.
Emily C. Timm The institution of Miss Timm has received research support from National Fragile X Foundation.
Rolando Acosta (Regeneron) No disclosure on file
Bharatkumar Koyani, MBBS Mr. Koyani has received personal compensation for serving as an employee of Regeneron. Mr. Koyani has stock in Regeneron.
Erin E. Robertson, PhD, AuD Dr. Robertson has received personal compensation for serving as an employee of Regeneron Pharmaceuticals Inc. Dr. Robertson has stock in Regeneron Pharmaceuticals Inc.
Matthew F. Wipperman, PhD Dr. Wipperman has received personal compensation for serving as an employee of Regeneron Pharmaceuticals. Dr. Wipperman has stock in Regeneron Pharmaceuticals.
Oren Levy, MD Dr. Levy has received personal compensation for serving as an employee of Regeneron Pharmaceuticals . Dr. Levy has stock in Regeneron Pharmaceuticals .
Joan A. O'Keefe, PhD Dr. O'Keefe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Department of Defense.